Amgen submits new drug application to FDA for sotorasib for treatment of advanced or metastatic non-small cell lung cancer with KRAS G12C mutation

The submission for this KRASG12C inhibitor is supported by phase 2 data from CodeBreaK 100 study in patients whose cancer had progressed despite prior treatment with chemotherapy and/or immunotherapy, which reported a durable anticancer activity with positive benefit-risk profile

Biospace Inc.